Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
ALK FISH analyses of multiple specimens occasionally yield inconsistent intersample results in lung cancer patients, posing clinical challenges requiring intensive analysis of all potential causative pre- and post- analytic factors. In this study, 19 patients (8M/11F) with inconsistent intersample A...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/7/1903 |
id |
doaj-b8a563250ccb4bd993566d9c4b70dd68 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhenya Tang Hui Chen Lingzhi Hong Guilin Tang Gokce A. Toruner Wei Wang Sinchita Roy Chowdhuri Wei Yin Hai Suk Jung Jun Gu Mark J. Routbort Jianjun Zhang Joseph D. Khoury L. Jeffrey Medeiros |
spellingShingle |
Zhenya Tang Hui Chen Lingzhi Hong Guilin Tang Gokce A. Toruner Wei Wang Sinchita Roy Chowdhuri Wei Yin Hai Suk Jung Jun Gu Mark J. Routbort Jianjun Zhang Joseph D. Khoury L. Jeffrey Medeiros Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes Cancers lung cancer ALK fluorescence in situ hybridization (FISH) next-generation sequencing (NGS) RNA sequencing (RNA-seq) tyrosine kinase inhibitor (TKI) |
author_facet |
Zhenya Tang Hui Chen Lingzhi Hong Guilin Tang Gokce A. Toruner Wei Wang Sinchita Roy Chowdhuri Wei Yin Hai Suk Jung Jun Gu Mark J. Routbort Jianjun Zhang Joseph D. Khoury L. Jeffrey Medeiros |
author_sort |
Zhenya Tang |
title |
Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes |
title_short |
Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes |
title_full |
Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes |
title_fullStr |
Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes |
title_full_unstemmed |
Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes |
title_sort |
inconsistent intersample alk fish results in patients with lung cancer: analysis of potential causes |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-07-01 |
description |
ALK FISH analyses of multiple specimens occasionally yield inconsistent intersample results in lung cancer patients, posing clinical challenges requiring intensive analysis of all potential causative pre- and post- analytic factors. In this study, 19 patients (8M/11F) with inconsistent intersample ALK FISH results were analyzed, representing 4.9% of patients assessed ≥ twice in our institution. Fifteen patients received ALK tyrosine kinase inhibitor(s) (TKIs). Nine patients died, and ten were alive for 8 to 74-month follow-ups (median, 40 months). Through strict and stringent laboratory and case-review policies, all postanalytic factors were excluded. Correlating clinical information, ALK results obtained by RNA sequencing (RNA-seq) and other concurrent tests, several pre-analytic factors were determined. A suboptimal specimen was likely the cause in three patients, supported by the failure of one or more concurrent tests or discrepant results between FISH and RNA-seq. ALK inhibition by TKIs might have been responsible for the change of <i>ALK</i> status from positive to negative in eight patients. Other potential explanations include the existence of multiple primary lung cancer lesions, tumor heterogeneity, and the clonal evolution of tumor cells, related or not to ALK TKI therapy. This study is helpful for both pathologists and clinicians encountering inconsistent and/or discrepant intersample results. |
topic |
lung cancer ALK fluorescence in situ hybridization (FISH) next-generation sequencing (NGS) RNA sequencing (RNA-seq) tyrosine kinase inhibitor (TKI) |
url |
https://www.mdpi.com/2072-6694/12/7/1903 |
work_keys_str_mv |
AT zhenyatang inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT huichen inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT lingzhihong inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT guilintang inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT gokceatoruner inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT weiwang inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT sinchitaroychowdhuri inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT weiyin inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT haisukjung inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT jungu inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT markjroutbort inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT jianjunzhang inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT josephdkhoury inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses AT ljeffreymedeiros inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses |
_version_ |
1724802398221762560 |
spelling |
doaj-b8a563250ccb4bd993566d9c4b70dd682020-11-25T02:35:57ZengMDPI AGCancers2072-66942020-07-01121903190310.3390/cancers12071903Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential CausesZhenya Tang0Hui Chen1Lingzhi Hong2Guilin Tang3Gokce A. Toruner4Wei Wang5Sinchita Roy Chowdhuri6Wei Yin7Hai Suk Jung8Jun Gu9Mark J. Routbort10Jianjun Zhang11Joseph D. Khoury12L. Jeffrey Medeiros13Departments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USAALK FISH analyses of multiple specimens occasionally yield inconsistent intersample results in lung cancer patients, posing clinical challenges requiring intensive analysis of all potential causative pre- and post- analytic factors. In this study, 19 patients (8M/11F) with inconsistent intersample ALK FISH results were analyzed, representing 4.9% of patients assessed ≥ twice in our institution. Fifteen patients received ALK tyrosine kinase inhibitor(s) (TKIs). Nine patients died, and ten were alive for 8 to 74-month follow-ups (median, 40 months). Through strict and stringent laboratory and case-review policies, all postanalytic factors were excluded. Correlating clinical information, ALK results obtained by RNA sequencing (RNA-seq) and other concurrent tests, several pre-analytic factors were determined. A suboptimal specimen was likely the cause in three patients, supported by the failure of one or more concurrent tests or discrepant results between FISH and RNA-seq. ALK inhibition by TKIs might have been responsible for the change of <i>ALK</i> status from positive to negative in eight patients. Other potential explanations include the existence of multiple primary lung cancer lesions, tumor heterogeneity, and the clonal evolution of tumor cells, related or not to ALK TKI therapy. This study is helpful for both pathologists and clinicians encountering inconsistent and/or discrepant intersample results.https://www.mdpi.com/2072-6694/12/7/1903lung cancerALKfluorescence in situ hybridization (FISH)next-generation sequencing (NGS)RNA sequencing (RNA-seq)tyrosine kinase inhibitor (TKI) |